HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.

AbstractBACKGROUND:
Raloxifene hydrochloride is a synthetic non-steroidal drug used for the prevention and treatment of post-menopausal osteoporosis. Pre-clinical and clinical data have shown that raloxifene may have a beneficial effect on leiomyomas. The aim of this prospective single-blind, randomized, placebo-controlled clinical trial was to evaluate the effectiveness of the addition of raloxifene to GnRH analogues on uterine, leiomyoma, and non-leiomyoma sizes, and on the occurrence of leiomyoma-related symptoms.
METHODS:
After randomization using a computer-generated list, 100 pre-menopausal women with symptomatic uterine leiomyomas received either leuprolide acetate depot plus raloxifene 60 mg daily (group A) or leuprolide plus placebo tablet (group B) for six cycles of 28 days. At baseline and after treatment, uterine, leiomyoma and non-leiomyoma sizes, and leiomyoma-related symptoms were evaluated for each woman. Analysis was by intention-to-treat method.
RESULTS:
After six cycles of treatment, a significant decrease in uterine, leiomyoma, and non-leiomyoma sizes was detected in both groups in comparison with baseline. At the same time, no significant difference in uterine and non-leiomyoma sizes was observed between the groups. Leiomyoma sizes were significantly (P < 0.05) lower in group A than in group B. No difference was observed in leiomyoma-related symptoms between groups throughout the study period.
CONCLUSIONS:
In women treated with GnRH analogue, the raloxifene administration induces a higher reduction of leiomyoma sizes.
AuthorsStefano Palomba, Tiziana Russo, Francesco Orio Jr, Libuse Tauchmanovà, Errico Zupi, Pier Luigi Benedetti Panici, Carmine Nappi, Annamaria Colao, Gaetano Lombardi, Fulvio Zullo
JournalHuman reproduction (Oxford, England) (Hum Reprod) Vol. 17 Issue 12 Pg. 3213-9 (Dec 2002) ISSN: 0268-1161 [Print] England
PMID12456626 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Delayed-Action Preparations
  • Placebos
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Leuprolide
Topics
  • Delayed-Action Preparations
  • Female
  • Hot Flashes
  • Humans
  • Leiomyoma (diagnostic imaging, drug therapy)
  • Leuprolide (administration & dosage, adverse effects)
  • Menorrhagia
  • Pain
  • Patient Dropouts
  • Placebos
  • Premenopause
  • Prospective Studies
  • Raloxifene Hydrochloride (administration & dosage, adverse effects)
  • Selective Estrogen Receptor Modulators (administration & dosage, adverse effects)
  • Ultrasonography
  • Uterine Neoplasms (diagnostic imaging, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: